aid: syntis-bio
name: Syntis Bio
description: >-
  Syntis Bio is a clinical-stage biopharmaceutical company in Boston, Massachusetts developing
  oral therapies that use the small intestine as a delivery site. Its SYNT platform (Synthetic
  Tissue-lining) applies a mussel-inspired polydopamine polymer coating transiently to specific
  tissues in the GI tract, sustaining therapeutic activity for up to 24 hours before being
  naturally cleared. The platform is being applied to nutrient exclusion for obesity, gut-restricted
  enzyme replacement for rare metabolic disorders such as homocystinuria and maple syrup urine
  disease, and oral bioavailability enhancement for peptides and biologics. Lead candidate SYNT-101
  is a once-daily oral pill intended to mimic aspects of gastric bypass by transiently blocking
  nutrient absorption in the duodenum. The company was co-founded in 2022 by MIT's Robert Langer and
  Giovanni Traverso with CEO Rahul Dhanda. Syntis Bio is a therapeutics developer and publishes no
  public API, developer program, SDK, or machine-readable specification.
image: https://syntis.bio/wp-content/uploads/2024/06/logo-header.svg
url: https://raw.githubusercontent.com/api-evangelist/syntis-bio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pass-no-api-surface
specificationVersion: '0.20'
created: '2026-08-29'
modified: '2026-08-29'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Drug Delivery
- Clinical Stage
- Obesity
- Rare Disease
- Health
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://syntis.bio/
- type: About
  url: https://syntis.bio/about/
- type: Blog
  url: https://syntis.bio/news/
- type: BlogRSS
  url: https://syntis.bio/feed/
- type: PrivacyPolicy
  url: https://syntis.bio/privacy-policy/
- type: TermsOfService
  url: https://syntis.bio/terms-of-use/
- type: Careers
  url: https://syntis.bio/careers/
- type: LinkedIn
  url: https://www.linkedin.com/company/syntis-bio/
- type: Twitter
  url: https://x.com/syntisbio
- type: DomainSecurity
  url: security/syntis-bio-domain-security.yml
- type: LLMsTxt
  url: llms/syntis-bio-llms.txt
x-enrichment:
  date: '2026-08-29'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    Syntis Bio is a clinical-stage biopharmaceutical company whose product is an oral drug-delivery
    polymer (SYNT / SYNT-101), not software; syntis.bio is a single WordPress marketing site with no
    api./developer./docs. subdomain resolving, no GitHub organization, and a 404 on every OpenAPI,
    GraphQL and /.well-known/ path probed.
  evidence:
  - url: https://syntis.bio/openapi.json
    status: 404
  - url: https://syntis.bio/.well-known/api-catalog
    status: 404
  - url: https://syntis.bio/.well-known/agent-card.json
    status: 404
  - url: https://syntis.bio/graphql
    status: 404
  - url: https://syntis.bio/
    status: 200
  checked: '2026-08-29'